Linomet Tablet 50/1000 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
MFDS item code 201505826 · Approved 2015.08.20
This product's status changed to Expired on 2025.08.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help patients with type 2 diabetes control their blood sugar levels. It is particularly effective when used in conjunction with a dietary and exercise regimen while administering sitagliptin and metformin together. This contributes to the stable management of blood sugar levels and reduces the risk of complications. Consistent use of this medication alongside healthy lifestyle habits positively impacts diabetes management. Therefore, this medication improves blood sugar control in type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined with consideration of the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin, which aid in blood sugar control. First, this medication may cause hypersensitivity reactions; therefore, if symptoms such as skin rashes, hives, or difficulty breathing occur, stop taking it immediately and consult a physician. Additionally, acute pancreatitis may occur; hence, if abdominal pain, vomiting, or severe abdominal discomfort arises, inform healthcare providers immediately. This medication is not safely administered to patients with decreased kidney function, especially in cases where creatinine clearance or glomerular filtration rate is low. It should also be avoided in conditions such as severe infection, dehydration, heart failure, or acute myocardial infarction. Patients undergoing radiologic iodine contrast studies should discontinue this medication for a specified period before and after the exam and can resume after kidney function is restored. Women who are pregnant or of childbearing age, as well as nursing mothers, should avoid using this medication. This medication may cause hypoglycemia; hence, blood sugar levels should be carefully monitored when meals are skipped, meals are irregular, or excessive exercise is undertaken. Particularly, when taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, so dose adjustments should be made according to physician's instructions. The metformin component can rarely cause a serious side effect known as lactic acidosis. If symptoms such as difficulty breathing, muscle pain, fatigue, or abdominal pain occur, consult healthcare providers immediately. Patients with impaired liver function or those consuming excessive alcohol should be cautious as the risk of lactic acidosis increases. Regular blood tests and kidney function tests should be performed while taking this medication, and supplementation for vitamin B12 deficiency may be necessary if it occurs. It is advised to pause taking this medication for a designated period before and after surgery and to restart only after the patient's condition stabilizes and kidney functions are confirmed normal. This medication has not been established for safety and efficacy in children, and elderly patients may face a risk of impaired kidney function, so dose adjustments and regular kidney function checks are necessary. In case of overdose, immediate medical attention should be sought for appropriate treatment, and dialysis may be required. Lastly, it is advised to avoid alcohol consumption while taking this medication, and to inform healthcare providers of any concurrent medication as interactions may occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure and is best kept at room temperature between 1 degree and 30 degrees Celsius. This will help maintain the medication's effectiveness for a long time.
Dark red oval film-coated tablet
28 tablets (14 tablets/PTPX2), 56 tablets (14 tablets/PTPX4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.